JP2023550310A5 - - Google Patents

Info

Publication number
JP2023550310A5
JP2023550310A5 JP2023528093A JP2023528093A JP2023550310A5 JP 2023550310 A5 JP2023550310 A5 JP 2023550310A5 JP 2023528093 A JP2023528093 A JP 2023528093A JP 2023528093 A JP2023528093 A JP 2023528093A JP 2023550310 A5 JP2023550310 A5 JP 2023550310A5
Authority
JP
Japan
Prior art keywords
vista
agonist
antibody
human
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023528093A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550310A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/058020 external-priority patent/WO2022098846A1/en
Publication of JP2023550310A publication Critical patent/JP2023550310A/ja
Publication of JP2023550310A5 publication Critical patent/JP2023550310A5/ja
Pending legal-status Critical Current

Links

JP2023528093A 2020-11-04 2021-11-04 虚血及び/または再灌流障害の治療/予防のためのvistaアゴニスト Pending JP2023550310A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063109584P 2020-11-04 2020-11-04
US63/109,584 2020-11-04
PCT/US2021/058020 WO2022098846A1 (en) 2020-11-04 2021-11-04 Vista agonist for treatment/prevention of ischemic and/or reperfusion injury

Publications (2)

Publication Number Publication Date
JP2023550310A JP2023550310A (ja) 2023-12-01
JP2023550310A5 true JP2023550310A5 (enExample) 2024-11-07

Family

ID=81458372

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023528093A Pending JP2023550310A (ja) 2020-11-04 2021-11-04 虚血及び/または再灌流障害の治療/予防のためのvistaアゴニスト

Country Status (8)

Country Link
US (1) US20230399405A1 (enExample)
EP (1) EP4240409A4 (enExample)
JP (1) JP2023550310A (enExample)
KR (1) KR20230142828A (enExample)
CN (1) CN116600826A (enExample)
AU (1) AU2021373781A1 (enExample)
CA (1) CA3197359A1 (enExample)
WO (1) WO2022098846A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024172543A1 (ko) * 2023-02-17 2024-08-22 뉴패스바이오(주) Igsf11-fc 융합 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 자가면역질환 또는 염증성 질환의 예방 또는 치료용 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104619722B (zh) * 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
CA2884704C (en) * 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
MX2015007446A (es) * 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
WO2017181109A1 (en) * 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof
PE20190115A1 (es) * 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso

Similar Documents

Publication Publication Date Title
Lane et al. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature
US8784822B2 (en) Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis
CN100562339C (zh) 小儿慢性关节炎相关疾病治疗剂
US8828393B2 (en) Methods for the therapy of inflammatory bowel disease using a type-1 interferon antagonist
CN111068062A (zh) 治疗白介素-6相关疾病的方法
MX2011003328A (es) Metodos para tratar inflamacion.
US20220332832A1 (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
JP2020521765A (ja) 慢性腎疾患の治療のためのデュラグルチド
Takagi et al. Cevimeline gargle for the treatment of xerostomia in patients with Sjögren’s syndrome
WO2017076804A1 (en) Treatment paradigm
JP2022514381A5 (enExample)
ZA200608884B (en) Methods of treating autoimmune and inflammatory diseases
AU2018228246A1 (en) Preventive or therapeutic agent for HTLV-1-associated myelopathy using low-dose anti-CCR4 antibody
JP2018065796A (ja) クローン病を治療するための医薬組成物
US9486475B2 (en) PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
CN1163272C (zh) Tnf拮抗剂作为用于治疗脓毒性疾病的药物的用途
JP2023550310A (ja) 虚血及び/または再灌流障害の治療/予防のためのvistaアゴニスト
EP4035663A1 (en) Use of progestin in treating cytokine release syndrome
Brunger et al. Obesity-induced AA amyloidosis: A diagnosis of exclusion
Schafernak et al. Co-existent crescentic glomerulonephritis and renal amyloidosis: a case report and literature review
JP2023505219A (ja) 再発性および/または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用
WO2024036385A1 (en) Treatment of myocarditis by administration of anti-interleukin-6 antibodies
US20210017278A1 (en) Treatment and Prophylaxis of Amyloidosis
JP2025529317A5 (enExample)
JP2017154975A (ja) クローン病を治療するための医薬組成物